Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model

Author： Gomis-González Maria   Busquets-Garcia Arnau   Matute Carlos   Maldonado Rafael   Mato Susana   Ozaita Andrés  

Publisher： MDPI

E-ISSN： 2073-4425|7|9|56-56

ISSN： 2073-4425

Source： Genes, Vol.7, Iss.9, 2016-08, pp. : 56-56

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Alterations in CA1 hippocampal synapses in a mouse model of fragile X syndrome

By  

GLIA, Vol. 66, Iss. 4, 2018-04 ,pp. : 789-800

John Wiley & Sons Inc

Access to resources Recommend Favorite

GABAB receptor‐mediated feed‐forward circuit dysfunction in the mouse model of fragile X syndrome

By  

THE JOURNAL OF PHYSIOLOGY, Vol. 593, Iss. 22, 2015-11 ,pp. : 5009-5024

John Wiley & Sons Inc

Access to resources Recommend Favorite

Transcriptional Reactivation of the FMR1 Gene. A Possible Approach to the Treatment of the Fragile X Syndrome†

By Tabolacci Elisabetta   Palumbo Federica   Nobile Veronica   Neri Giovanni  

Genes, Vol. 7, Iss. 8, 2016-08 ,pp. : 49-49

MDPI

Access to resources Recommend Favorite

Therapeutic Effect of Losartan, an Angiotensin II Type 1 Receptor Antagonist, on CCl4-Induced Skeletal Muscle Injury

By Hwang Ok-Kyung   Park Jin-Kyu   Lee Eun-Joo   Lee Eun-Mi   Kim Ah-Young   Jeong Kyu-Shik  

International Journal of Molecular Sciences, Vol. 17, Iss. 2, 2016-02 ,pp. : 227-227

MDPI

Access to resources Recommend Favorite

In silico mapping of allosteric ligand binding sites in type‐1 cannabinoid receptor

By  

BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, Vol. 65, Iss. 1, 2018-01 ,pp. : 21-28

John Wiley & Sons Inc

Access to resources Recommend Favorite